licence agreement

Transthyretin amyloid cardiomyopathy: Alexion granted an exclusive worldwide licence to develop, manufacture and commercialise NI006 as part of an agreement with Neurimmune AG

Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal…

2 years ago